Regeneron Pharma begins human trials of Covid-19 antibody ‘cocktail’

US-based Regeneron Pharmaceuticals has begun human trials of its antibody ‘cocktail’ as a treatment for Covid-19

The antibody which is called REGN-COV2, contains an antibody made by Regeneron and a second isolated from humans who recovered from Covid-19.

George Yancopoulos .Chief Scientific Officer, said“If it goes perfectly well, within a week or two we will move to the second phase. Within a month or so of that we will have clear data that this is or isn’t working. By the end of summer, we could have sufficient data for broad utilization”

Regeneron said its treatment could be useful even if a Covid-19 vaccine is developed since the elderly and people with compromised immune systems often do not respond well to vaccines.

The firm also plans to study REGN-COV2 for preventing the infection in people at high risk of exposure.